Cite
HARVARD Citation
Wang, J. et al. (2020). A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. Expert opinion on investigational drugs. pp. 755-762. [Online].